Devan V. Mehrotra - Concepedia

Author

Devan V. Mehrotra

Merck & Co., Inc., Rahway, NJ, USA (United States)ORCID

Also Known As

Brown, E.R., D V Mehrotra, D. Mehrotra, D. V. MEHROTRA, D. V. Mehrotra, D.V. Mehrotra, DEVAN V. MEHROTRA, Devan Mehrotra, Devan V Mehrotra, Devan V. Mehrotra

150

Publications

6.3K

Citations

H-Index

126

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)United States Military Academy Fred Hutch Cancer Center Decision Sciences (United States)University of Washington

About

Devan V. Mehrotra is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, statistics, and biostatistics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	19	26	3.3K
2	Engineering	5	5	266
3	Business	1	1	72
4	Health Sciences	1	1	14
5	Management	1	1	37

Devan V. Mehrotra

Publications

5.7K

Citations

H-Index

Page 1

	Year	Citations
Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial Susan Buchbinder, Devan V. Mehrotra, Ann Duerr, The Lancet VaccinationTest-of-concept TrialTreatment And PreventionImmunologyVaccine Trial	2008	1.7K
HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case–cohort analysis M. Juliana McElrath, Stephen C. De Rosa, Zoe Moodie, The Lancet VaccinationSexual HealthHuman RetrovirusImmunodeficienciesImmunology	2008	697
Safety and Immunogenicity of a Replication‐Incompetent Adenovirus Type 5 HIV‐1 Clade B<i>gag/pol/nef</i>Vaccine in Healthy Adults Frances Priddy, Deborah D. Brown, James G. Kublin, Clinical Infectious Diseases	2008	238
Should baseline be a covariate or dependent variable in analyses of change from baseline in clinical trials? G. Frank Liu, Kaifeng Lu, Robin Mogg, Statistics in Medicine	2009	236
A Cautionary Note on Exact Unconditional Inference for a Difference between Two Independent Binomial Proportions Devan V. Mehrotra, Ivan S. F. Chan, Roger L. Berger Biometrics	2003	134
Use of the false discovery rate for evaluating clinical safety data Devan V. Mehrotra, Joseph F. Heyse Statistical Methods in Medical Research	2004	123
AIDS Clinical Trials Group 5197: A Placebo‐Controlled Trial of Immunization of HIV‐1–Infected Persons with a Replication‐Deficient Adenovirus Type 5 Vaccine Expressing the HIV‐1 Core Protein Robert T. Schooley, John Spritzler, Hongying Wang, The Journal of Infectious Diseases	2010	120
Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine Trials Devan V. Mehrotra, Holly Janes, Thomas R. Fleming, Annals of Internal Medicine VaccinationSeveral Vaccine CandidatesMedicineVaccine TargetCovid-19 Pandemic	2020	114
Recommendations for safety planning, data collection, evaluation and reporting during drug, biologic and vaccine development: a report of the safety planning, evaluation, and reporting team Brenda Crowe, H. Amy Xia, Jesse A. Berlin, Clinical Trials	2009	113
Detection of HIV Vaccine-Induced Cell-Mediated Immunity in HIV-Seronegative Clinical Trial Participants Using an Optimized and Validated Enzyme-Linked Immunospot Assay Sheri Dubey, J. Clair, Tong‐Ming Fu, JAIDS Journal of Acquired Immune Deficiency Syndromes ImmunodeficienciesImmunologyImmunodominanceHiv ElispotImmunotherapy	2007	93

Page 1